<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>n8k217.htm
<DESCRIPTION>PFIZER INC. FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Pfizer Inc. 8-K </TITLE>
<BODY bgColor=#ffffff>
<DIV align=right> </DIV>
<P align=center><STRONG>UNITED STATES</STRONG></P>
<P align=center><STRONG><FONT size=4>SECURITIES AND EXCHANGE COMMISSION</FONT></STRONG></P>
<P align=center><STRONG>Washington, D.C. 20549</STRONG></P>
<P align=center><STRONG>FORM 8-K</STRONG></P>
<P align=center>CURRENT REPORT </P>
<P align=center>PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
  SECURITIES EXCHANGE ACT OF 1934</P>
<P align=center>Date of Report (Date of earliest event reported): <strong>February
3,
2017 (February 2, 2017)</strong></P>
<P align=center><STRONG>PFIZER INC.</STRONG><BR>
  (Exact name of registrant as specified in its charter)</P>
<TABLE width="87%" border=0>
  <TR>
    <TD width="43%">
      <DIV align=center><STRONG>Delaware</STRONG></DIV>
    </TD>
    <TD width="25%">
      <DIV align=center><STRONG>1-3619</STRONG></DIV>
    </TD>
    <TD width="32%">
      <DIV align=center><STRONG>13-5315170</STRONG></DIV>
    </TD>
  </TR>
  <TR>
    <TD width="43%">
      <DIV align=center>(State or other Jurisdiction of incorporation)</DIV>
    </TD>
    <TD width="25%">
      <DIV align=center>(Commission File Number)</DIV>
    </TD>
    <TD width="32%">
      <DIV align=center>(I.R.S. Employer Identification No.)</DIV>
    </TD>
  </TR>
  <TR>
    <TD width="43%">
      <BLOCKQUOTE>
        <P align=center><STRONG>235 East 42nd Street <BR>
          New York, New York<BR>
          </STRONG>(Address of principal executive offices)<STRONG><BR>
          </STRONG></P>
      </BLOCKQUOTE>
    </TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="32%">
      <DIV align=center><STRONG>10017</STRONG><BR>
        (Zip Code)</DIV>
    </TD>
  </TR>
</TABLE>
<BLOCKQUOTE>
  <BLOCKQUOTE>
    <P align=center> Registrant's telephone number, including area code:
    <DIV align=center> (212) 733-2323 <br>
      <strong><br>
      </strong><u>Not Applicable</u>	<br>
      (Former Name or Former Address, if changed since last report)<br>
    </DIV>
  </BLOCKQUOTE>
</BLOCKQUOTE>
<P align=left>Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):</P>
<P> [&nbsp; &nbsp;] Written communication pursuant to Rule 425 under the Securities
  Act (17 CFR 230.425)</P>
<P> [&nbsp; &nbsp;] Soliciting material pursuant to Rule 14a-12 under the Exchange
  Act (17 CFR 240.14a-12)</P>
<P> [&nbsp; &nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b)
  under the Exchange Act (17 CFR 240.14d-2(b))</P>
<P> [ &nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 13e-4(c)
  under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P>&nbsp;</P>
<table width="87%" border=0 height="217">
  <tr>
    <td width="13%" height="66"><b>Item 8.0</b><strong>1</strong></td>
    <td width="87%" height="66"><p><strong>Other Events</strong></p></td>
  </tr>
  <tr>
    <td height="145" colspan="2">
    <p>On February 2, 2017, Pfizer Inc. (&quot;Pfizer&quot;) entered into an accelerated
	share repurchase agreement with Citibank N.A. (&quot;Citibank&quot;) to repurchase $5 billion of
	Pfizer's common stock.&nbsp; Approximately 126 million of the shares to be
	repurchased under the transaction will be received by Pfizer on February 6,
	2017.<br><br>At settlement of the agreement, which is expected to occur
	during or prior to the third quarter of 2017, Citibank may be required to deliver
	additional shares of Pfizer's common stock to Pfizer, or, under certain
	circumstances, Pfizer may be required to deliver shares of its common stock
	or may elect to make a cash payment to Citibank, with the number of shares to
	be delivered or the amount of such payment based on the volume-weighted average price of
	Pfizer's common stock during the term of the transaction.<br><br>This
	agreement was entered into pursuant to Pfizer's previously announced share
	repurchase authorization.<br><br>The press release relating to the
	accelerated share repurchase agreement is filed as an exhibit to this Form
	8-K and is incorporated herein by reference. </p>
	<p>&nbsp;</p>
	<p>&nbsp;</p></td>
  </tr>
</table>
<p>&nbsp;</p>
<table width="80%" border=0>
  <tr>
    <td width="21%"><strong>Item 9.01</strong></td>
    <td width="75%"><strong> Financial Statements and Exhibits.</strong></td>
    <td width="4%">&nbsp;</td>
  </tr>
</table>
<table width="80%" border=0>
  <tr>
    <td width="24%">(d) Exhibits<br></td>
    <td width="71%">&nbsp;</td>
    <td width="5%">&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><u>Exhibit No.</u></td>
    <td><u>Description</u></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>99.1</td>
    <td> Press Release of Pfizer Inc. dated February 3, 2017</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td width="24%">&nbsp;</td>
    <td width="71%">&nbsp;</td>
    <td width="5%">&nbsp;</td>
  </tr>
</table>
<p align="left">&nbsp;</p>
<p align="center"><STRONG>SIGNATURE</STRONG></p>
<P>Under the requirements of the Securities Exchange Act of 1934, the registrant
  has caused this report to be signed on its behalf by the authorized undersigned.</P>
<TABLE width="82%" border=0>
  <TR>
    <TD width="33%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="61%">
      <DIV align=left>PFIZER INC.</DIV>
    </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp; </TD>
  </TR>
  <TR>
    <TD height=41>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
      <DIV align=left>By: <U>/s/ &nbsp;Margaret M. Madden</U><BR>
        Margaret M. Madden</DIV>
    </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
      <DIV align=left>Title: Vice President and Corporate Secretary<br>
    </DIV></TD>
  </TR>
  <TR>
    <TD>Dated: February 3, 2017</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief  Governance Counsel</TD>
  </TR>
</TABLE>
<p>&nbsp;</p>
<BLOCKQUOTE>
  <BLOCKQUOTE>
    <BLOCKQUOTE>
      <BLOCKQUOTE>
        <BLOCKQUOTE>
          <BLOCKQUOTE>
            <BLOCKQUOTE>&nbsp;</BLOCKQUOTE>
          </BLOCKQUOTE>
          <p><b>EXHIBIT INDEX</b></p>
        </BLOCKQUOTE>
      </BLOCKQUOTE>
    </BLOCKQUOTE>
  </BLOCKQUOTE>
</BLOCKQUOTE>
<table width="81%" border=0>
  <tr>
    <td width="17%">
      <p><b>Number</b></p>
    </td>
    <td width="83%"><b>Description</b></td>
  </tr>
  <tr>
    <td width="17%">99.1</td>
    <td width="83%"> Press Release of Pfizer Inc. dated February 3, 2017</td>
  </tr>
</table>
<P align=center>&nbsp;</P>
</TEXT>
</DOCUMENT>